Literature DB >> 25737145

The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy.

Tae Chung1, Lisa Christopher-Stine2, Julie J Paik2, Andrea Corse3, Andrew L Mammen4.   

Abstract

INTRODUCTION: To characterize cellular infiltrates in muscle biopsies from patients with anti-3-hydroxy-3-methyl-gulatryl-CoA reductase (HMGCR)-associated myopathy.
METHODS: Biopsies from 18 anti-HMGCR myopathy and 7 control dermatomyositis patients were analyzed.
RESULTS: CD4+ and CD8+ T-cells were scattered within the endomysium in 50% of anti-HMGCR biopsies. All anti-HMGCR biopsies included increased endomysial and/or perivascular CD163+ M2 macrophages; CD11c+ M1 macrophages were present in 18.8%. CD123+ plasmacytoid dendritic (PD) cells were observed within the endomysium and perivascular spaces in 62.5% of anti-HMGCR biopsies. Membrane attack complex was deposited on endothelial cells in 50% and on the sarcolemma of nonnecrotic muscle fibers in 85.7% of anti-HMGCR cases. Major histocompatibility complex class I antigen was up-regulated in 87.5% of the anti-HMGCR cases.
CONCLUSIONS: In addition to necrosis, scattered CD4+, CD8+, and PD cells are characteristic of anti-HMGCR myopathy. Predominant M2 polarization suggests infiltrating macrophages are more likely to be involved with tissue repair than destruction.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  anti-HMGCR myopathy; autoimmune myopathy; immune-mediated necrotizing myopathy; muscle histology; myositis

Mesh:

Substances:

Year:  2015        PMID: 25737145      PMCID: PMC4510021          DOI: 10.1002/mus.24642

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  24 in total

1.  Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study.

Authors:  Paolo Confalonieri; Laura Oliva; Francesca Andreetta; Rossella Lorenzoni; Patrizia Dassi; Elisabetta Mariani; Lucia Morandi; Marina Mora; Ferdinando Cornelio; Renato Mantegazza
Journal:  J Neuroimmunol       Date:  2003-09       Impact factor: 3.478

2.  119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.

Authors:  Jessica E Hoogendijk; Anthony A Amato; Bryan R Lecky; Ernest H Choy; Ingrid E Lundberg; Michael R Rose; Jiri Vencovsky; Marianne de Visser; Richard A Hughes
Journal:  Neuromuscul Disord       Date:  2004-05       Impact factor: 4.296

3.  Diagnostic significance of membrane attack complex and vitronectin in childhood dermatomyositis.

Authors:  Ryoichi Sakuta; Nobuyuki Murakami; Yuko Jin; Toshiro Nagai; Ikuya Nonaka; Ichizo Nishino
Journal:  J Child Neurol       Date:  2005-07       Impact factor: 1.987

4.  Inflammatory myopathy with abundant macrophages and dermatomyositis: two stages of one disorder or two distinct entities?

Authors:  Anna Brunn; Volkmar J Hans; Silke Vogelgesang; Martina Deckert
Journal:  Acta Neuropathol       Date:  2009-12       Impact factor: 17.088

Review 5.  Analysis of macrophages, activated cells and T cell subsets in inflammatory myopathies using monoclonal antibodies.

Authors:  R Giorno; S P Ringel
Journal:  Pathol Immunopathol Res       Date:  1986

Review 6.  Inflammatory processes in muscle injury and repair.

Authors:  James G Tidball
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-02       Impact factor: 3.619

7.  Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis.

Authors:  Steven A Greenberg; Jack L Pinkus; Geraldine S Pinkus; Travis Burleson; Despina Sanoudou; Rabi Tawil; Richard J Barohn; David S Saperstein; Hannah R Briemberg; Maria Ericsson; Peter Park; Anthony A Amato
Journal:  Ann Neurol       Date:  2005-05       Impact factor: 10.422

8.  Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells.

Authors:  K Arahata; A G Engel
Journal:  Ann Neurol       Date:  1984-08       Impact factor: 10.422

9.  High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.

Authors:  M Basta; M C Dalakas
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

10.  Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells.

Authors:  Guillaume Page; Guillaume Chevrel; Pierre Miossec
Journal:  Arthritis Rheum       Date:  2004-01
View more
  21 in total

Review 1.  A case of statin-associated immune-mediated necrotizing myopathy with atypical biopsy features.

Authors:  Mark M Zaki; Zain M Virk; Diego Lopez; Jenna Klubnick; Jared T Ahrendsen; Hemant Varma; Vasileios Kyttaris; Ilana Abeles
Journal:  Eur J Rheumatol       Date:  2021-01-01

Review 2.  Autoimmune Myopathies.

Authors:  Andrew L Mammen
Journal:  Continuum (Minneap Minn)       Date:  2016-12

3.  HMGCR antibody-associated myopathy as a paraneoplastic manifestation of esophageal carcinoma.

Authors:  Koyo Tsujikawa; Kazuhiro Hara; Yoshinao Muro; Hirotaka Nakanishi; Yukiko Niwa; Masahiko Koike; Seiya Noda; Yuichi Riku; Kentaro Sahashi; Naoki Atsuta; Mizuki Ito; Yoshie Shimoyama; Masashi Akiyama; Masahisa Katsuno
Journal:  Neurology       Date:  2016-07-22       Impact factor: 9.910

Review 4.  Immune-mediated necrotizing myopathy.

Authors:  C Bergua; H Chiavelli; J P Simon; O Boyer; F Jouen; W Stenzel; J Martinet
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

Review 5.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

Review 6.  Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.

Authors:  Leandro Ladislau; Louiza Arouche-Delaperche; Yves Allenbach; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2018-08-03       Impact factor: 4.592

Review 7.  The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.

Authors:  L G Rider; K Nistala
Journal:  J Intern Med       Date:  2016-03-30       Impact factor: 8.989

Review 8.  Immune-Mediated Necrotizing Myopathy.

Authors:  Iago Pinal-Fernandez; Maria Casal-Dominguez; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2018-03-26       Impact factor: 4.592

Review 9.  Autoimmune Myopathies: Updates on Evaluation and Treatment.

Authors:  Emer R McGrath; Christopher T Doughty; Anthony A Amato
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

10.  213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015.

Authors:  Olivier Benveniste; Lisa G Rider
Journal:  Neuromuscul Disord       Date:  2016-05-27       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.